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Summary
The receptor tyrosine kinase HER2 enhances tumor metastasis; however, its role in homing to metastatic organs is poorly
understood. The chemokine receptor CXCR4 has recently been shown to mediate the movement of malignant cancer cells
to specific organs. Here, we show that HER2 enhances the expression of CXCR4, which is required for HER2-mediated
invasion in vitro and lung metastasis in vivo. HER2 also inhibits ligand-induced CXCR4 degradation. Finally, a significant
correlation between HER2 and CXCR4 expression was observed in human breast tumor tissues, and CXCR4 expression
correlated with a poor overall survival rate in patients with breast cancer. These results provide a plausible mechanism
for HER2-mediated breast tumor metastasis and establish a functional link between HER2 and CXCR4 signaling pathways.
Introduction Zhou and Hung, 2003), its role in tumor progression is still far
from being completely understood, especially its role in targeted
The aberrant activation of the human epithelial growth factor metastasis, such as homing to the lung.
receptor (HER, ErbB) family of receptor tyrosine kinases (RTKs), Metastasis, the major cause of morbidity and mortality in
which includes HER1 (ErbB1, epithelial growth factor [EGFR]), most cancers, is a complex pathophysiological process that
HER2 (ErbB2, neu), HER3, and HER4, has been implicated in is highly organ selective and involves numerous interactions
tumor growth and progression (Yarden and Sliwkowski, 2001). between the cancer cells and the host (Fidler and Hart, 1982;
Of the four HER family members, HER2 is the most potent Steeg, 2003; Yeatman and Nicolson, 1993). Although many mol-
oncoprotein. HER2 is amplified or overexpressed in about 30% ecules have been implicated in cancer metastasis, the detailed
of breast cancers and other cancers and is associated with mechanism of organ-specific tumor metastasis is still not com-
a poor clinical outcome, including a positive correlation with pletely understood. Recently, it was suggested that chemokine
metastasis (Slamon et al., 1989; Yu and Hung, 2000). In addition, stromal cell-derived factor-1 (SDF-1, also known as CXC
chemokine ligand 12) and its receptor, CXCR4, are involvedHER2 increases the metastatic potential in murine and human
cancer cell lines (Tan et al., 1997; Yarden and Sliwkowski, 2001; in breast cancer metastasis (Liotta, 2001; Muller et al., 2001).
Chemokines are a superfamily of small, cytokine-like peptides,Yu and Hung, 1991, 2000; Yu et al., 1994) and induces mammary
tumors and lung metastases in transgenic animal models (Guy which are divided into subclasses according to the motifs on
their first two cysteine residues in the N terminus (Proudfoot,et al., 1992; Muller et al., 1988). It has already been used as a
target for cancer therapies such as trastuzumab (Herceptin), an 2002; Rossi and Zlotnik, 2000). Through interaction with chemo-
kine receptors, chemokines induce cytoskeletal rearrangementanti-HER2 antibody that has shown a good clinical benefit in
patients with HER2-driven metastatic breast cancer (Slamon et of hematopoietic cells, increase their adhesion, and direct them
to migrate to a home-specific organ. Chemokine receptors are Gal., 2001). Although the functionality of HER2 in breast cancer
has been extensively studied (Yarden and Sliwkowski, 2001; protein-coupled seven-transmembrane receptors (GPCR), and
S I G N I F I C A N C E
Metastasis is the main cause of morbidity and mortality in most cancers. Recently, CXC chemokine receptor 4 (CXCR4) was found
to play a very important role in the targeted metastasis of breast cancer; the CXCR4 is expressed in malignant breast cancer cells,
while the natural ligand stromal cell-derived factor-1 (SDF-1) is released by certain metastatic organs. Overexpression of HER2
enhances the metastatic potential and correlates with poor prognosis. Here, we show that HER2 upregulates CXCR4 expression, and
the inhibition of CXCR4 expression suppresses HER2-induced malignancy in vitro and in vivo lung metastasis. Our data reveal the
mystery for HER2-mediated homing to metastatic organs and provide a crucial link between the chemokine receptor CXCR4 and
the receptor tyrosine kinase HER2 in tumor progression and metastasis.
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Figure 1. HER2 enhances the chemokine receptor CXCR4 expression
A: MDA-MB-435 cells and their HER2 stable transfectants were stained for the CXCR4 antibody (MAB 172; R&D) and analyzed using FACS. The upper panel
shows CXCR4 expression in HER2/435 (blue) and 435/neo (red) vector control cell lines compared with an isotype control preparation (green). The lower
panel shows similar staining for NIH 3T3 (red) and its HER2 transfectant (blue).
B: HER2 enhances CXCR4 expression demonstrated by immunofluorescent staining. 435/neo and 435/HER2 cells were stained with anti-HER2 (green) and
anti-CXCR4 (red) antibodies and examined under a confocal microscope (Olympus).
C: Herceptin reduces CXCR4 level in HER2-overexpressing cells. 435/HER2, 435/neo, and BT-474 cells were treated with Herceptin 15 g/ml for 36 hr (red);
BT-474 cells were treated with HER2 siRNA and subjected for FACS analysis.
D: Western blot supporting CXCR4 (top panel) expression and HER2 status (second panel) of MDA-MB-435 cells, two HER2 stable transfectants, and BT-474
cells used in FACS. The human actin was used as a loading control for the Western blot (bottom). Band intensities were quantitated, and the relative ratios
of CXCR4 intensity among the different treatments were shown below the first lane.
E: Analysis of CXCR4 mRNA expression. 435/neo cells and two 435/HER2 stable transfectants were harvested, and total RNA was prepared for Northern
blotting using human CXCR4 (top) cDNA probes. The human GAPDH and total 18S and 28S ribosomal RNA were used as a loading control (second and
bottom panel).
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CXCR4 is one of the best-characterized chemokine receptors. independent HER2 stable transfectants of MDA-MB-435 breast
cancer cells by Western blot (Figure 1D, left panel) and alsoIn addition to inducing leukocyte trafficking (Hernandez et al.,
2003), CXCR4 is essential for B cell lymphopoiesis and myelo- observed in the NIH 3T3 cell and its HER2 stable transfectant
(Figure 1A). The increase in CXCR4 expression by HER2 waspoiesis (Nagasawa et al., 1996), gastrointestinal tract vasculari-
zation (Tachibana et al., 1998), neuronal and germ cell migration further supported by fluorescence confocal microscopy (Figure
1B). The 435/HER2 cells expressed much higher levels of(Knaut et al., 2003; Kunwar and Lehmann, 2003; Zou et al.,
1998), and HIV invasion of host cells (Connor et al., 1997; Scar- CXCR4 than did the vector control cells (435/neo) (red) (Figure
1B); the HER2 status was confirmed using an anti-HER2 anti-latti et al., 1997). Moreover, CXCR4 and its ligand, SDF-1, play
an important role in the targeted metastasis of breast cancer body staining (green). To further examine whether HER2 is re-
quired for the enhanced CXCR4 expression in HER2-overex-(Liotta, 2001; Muller et al., 2001). Chemokines such as SDF-1
are released in high amounts by certain organs, such as lung, pressing cancer cells, we used a HER2-specific monoclonal
antibody, Herceptin, that is known to downregulate HER2 (Car-bone, and liver. Malignant breast cancer cells, which express
the chemokine receptor CXCR4, invade the extracellular matrix ter et al., 1992; Klos et al., 2003; Pietras et al., 1998) and found
that Herceptin decreases the CXCR4 expression in 435/HER2and circulate in the blood and lymphatic vessels. The attraction
between SDF-1 and CXCR4 causes breast cancer cells to cells, compared to control IgG. However, Herceptin does not
affect the CXCR4 expression in 435/neo cells (Figure 1C). Down-leave the circulation and migrate into organs with large amounts
of chemokines, where the cancer cells proliferate, induce angio- regulating CXCR4 by Herceptin was also observed in endoge-
nous HER2 overexpressing BT-474 cells by FACS (Figure 1C)genesis, and form metastatic tumors. CXCR4 is also involved
in the metastasis of prostate cancer to the bone marrow (Taich- and Western blot (Figure 1D, middle panel). Similar results were
also observed using RNA interference to deplete HER2 expres-man et al., 2002) and of colon cancer to the liver (Zeelenberg
et al., 2003). sion (Figures 1C and 1D, right panel). Therefore, these results
indicate that HER2 is able to increase the expression of theIn an attempt to understand how HER2 overexpression in-
creases metastatic potential and, in particular, homing to its chemokine receptor CXCR4.
We further investigated the molecular mechanism behindmetastatic organs, which cause the majority of cancer patient
deaths (Hortobagyi, 1998; Landis et al., 1999; Slamon et al., HER2-induced CXCR4 expression. HER2 does not enhance
CXCR4 mRNA level, as shown by Northern blot analysis (Figure2001), we found that HER2 enhances the expression of CXCR4.
CXCR4 expression was also shown to predict poor patient sur- 1E). Therefore, it is likely that HER2 regulates CXCR4 at the
protein level. We used metabolic labeling assays to detect thevival. Furthermore, we found that CXCR4 is required for HER2-
protein synthesis and degradation of CXCR4. Pulse-labelingmediated metastatic potential in vitro and in vivo. Our data
studies demonstrated that HER2 increases the protein synthesisestablish a molecular mechanism whereby HER2-overexpress-
rate of the CXCR4 receptor, which is 2.5-fold faster than theing cancer cells home to specific organs and provide crucial
control before the first 2 hr (Figure 1F). Pulse-chase experimentsevidence of a functional link between the HER2 and CXCR4
(Figure 1G) indicated that HER2 only slightly lowers the basalsignaling pathways.
protein degradation rate of CXCR4 (please note that this is
different from the ligand-dependent degradation that is de-Results
scribed in Figure 3B); however, considering the standard devia-
tion from three independent experiments, there is no statisticalHER2 enhances the chemokine receptor
CXCR-4 expression difference between them. Thus, the increased CXCR4 protein
level in the HER2-expressing cells is primarily caused by en-It is well known that HER2 enhances cancer invasion and lung
metastasis (Tan et al., 1997; Yarden and Sliwkowski, 2001; Yu hanced translational rate (Figure 1F) and is less influenced by
the basal degradation rate (Figure 1G). Since HER2 can activateand Hung, 2000), and the chemokine receptor CXCR4 is in-
volved in the metastasis of breast cancer to the lung (Muller et Akt (Zhou et al., 2000), which is known to stimulate the mamma-
lian target of rapamycin (mTOR) to enhance protein synthesisal., 2001). We hypothesized that CXCR4 plays a role in HER2-
mediated metastasis. To test this hypothesis, we examined (Gingras et al., 2001), we next examined whether the enhance-
ment of CXCR4 protein synthesis by HER2 might occur throughCXCR4 expression by fluorescence-activated cell sorting (FACS)
analysis and found that CXCR4 expression was 2.8  0.6-fold the PI-3K/Akt/mTOR pathway. If mTOR is involved in the HER2-
enhanced CXCR4 translation, blockage of the mTOR activityhigher in the HER2 transfectants of MDA-MB-435 breast cancer
cells (435/HER2) than that in the vector control cells (435/neo) and its upstream signals such as PI-3 kinase and HER2 tyrosine
kinase should inhibit HER2-induced CXCR4 expression. Con-(Figure 1A). In addition, this phenomenon was supported in two
F: Metabolic pulse-labeling experiment. [35S]Met-Cys was used to measure the protein synthesis rate of CXCR4 in 435/neo and 435/HER2 cells (upper panel),
and the relative synthesis rates of CXCR4 protein and standard deviation (SD) were plotted in the bottom panel. The experiments were repeated three
times.
G: Pulse-chase assay to measure the protein degradation rate. Serum-starved 435/neo and 435/HER2 cells were pretreated with [35S]Met-Cys, and then
the cells were rinsed and incubated in medium containing unlabeled Met-Cys for the indicated time prior to preparation of cell lysates and immunoprecipita-
tion of CXCR4. All the experiments were repeated three times. Mean and SD are shown below the lanes.
H: Effect of HER2/PI-3K/Akt/mTOR pathway on CXCR4 expression. After overnight serum starvation, in the presence of 10% serum stimulation, different
inhibitors of HER2 (AG825, 100 M [AG]), PI-3K (Wortmannin, 100 M [WMN], and LY294002, 50 mM [LY]), and mTOR (rapamycin, 100 M [Rap]) were used
to treat MDA-MB-435 HER2 stable transfectants for 6 hr. The effects of all these inhibitors on the activity of HER2, PI-3K/Akt, and FRAP were relatively assessed
by phosphorylation of tyrosine residue of HER2, phosphorylation of Akt at residue serine 473, and phosphorylation of p70 S6k at residue threonine 389.
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Figure 2. CXCR4 is required for HER2-enhanced invasion, migration, and adhesion in vitro
A: Invasive assays were performed using the Boyden Chamber assay coated with Matrigel, which mimics basement membrane composition, and SDF-1,
a ligand for CXCR4, as a chemoattractive agent in the lower chamber. For the blocking assay, either CXCR4 blocking antibody (1–10 g/ml) or Herceptin
(5 g/ml; 15 g/ml) was added into cell culture. Cells were counted in triplicate wells and in five identical experiments.
B–E: Quantification of invasion assays. *p  0.05.
F: The migration assay was performed in a manner similar to the invasive assay, except in the absence of Matrigel. Quantification of migration is shown.
*p  0.05.
G and H: HER2 significantly enhances adhesion to endothelial cells. Cell-to-cell adhesion was quantified using a fluorescent plate reader. Data are presented
as mean raw fluorescent counts per well of the mean. *p  0.05.
sistent with this notion, treatment of different inhibitors, includ- Similar results were observed for 3T3 and 3T3/HER2 cells (Fig-
ures 2A and 2C) and endogenous HER2-overexpressing BT-474ing the inhibitors for HER2 tyrosine kinase (AG825), PI-3 kinase
(Wortmannin and LY294002), and mTOR (rapamycin) indeed cells (Figure 2D). Since Herceptin downregulated CXCR4 expres-
sion (Figures 1C and 1D), the SDF-1-induced in vitro invasiveinhibited CXCR4 expression in 435/HER2 cells. The phosphory-
lation of tyrosine residue of HER2, phosphorylation of Akt at activity was also inhibited by Herceptin in two HER2-overex-
pressing cell lines, 435/HER2 and BT-474 (Figures 2D and 2E).residue serine 473, and phosphorylation of p70S6k at residue
threonine 389 were also examined as controls for proper effects Thus, these results indicate that upregulation of CXCR4 by
HER2 is required for in vitro invasion induced by SDF-1.of these inhibitors (Figure 1H). The result suggests that PI-3K/
Akt/mTOR pathway may attribute to the HER2-induced CXCR4 Cancer cell invasion involves a sequential series of critical
steps, including adhesion to endothelial cells and migration to-expression.
ward chemotactic factors. To better understand which steps of
HER2-induced invasion CXCR4 may contribute to, we examinedCXCR4 is crucial for HER2-induced invasion, migration,
and adhesion activities in vitro the migration and adhesion activities of HER2 stable transfec-
tants and their parental cells in response to SDF-1 stimulation.Because HER2 induces CXCR4 expression, and both HER2 and
interaction between CXCR4 and SDF-1 play an important role Migration was inhibited by a CXCR4-blocking antibody but not
by the mouse IgG antibody (Figure 2F), indicating that CXCR4in metastasis, we examined whether SDF-1/CXCR4 interaction
contributes to HER2-driven invasive activities. Invasion assays is required for HER2-enhanced migration. The phenomenon was
observed in 435/neo and 435/HER2 cells (Figure 2F) and in 3T3were performed using the Boyden Chamber coated with Matri-
gel. It was clear that SDF-1 stimulated the in vitro invasive and 3T3/HER2 cells (data not shown). The adhesion assay, which
measures adherence to cultured endothelial cells, also indicatedactivity in 435/HER2 cells but not in the 435/neo control cells.
Moreover, the SDF-1-induced invasive activity was inhibited that the CXCR4-blocking antibody inhibited HER2-induced adhe-
sion activity in BT-474 and 3T3/HER2 cells (Figures 2G and 2H).in a concentration-dependent manner by a CXCR4-blocking
antibody (Figures 2A and 2B), but not by a control IgG antibody. Taken together, these results demonstrate that HER2-induced
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CXCR4 expression plays a critical role in increasing the migra- CXCR4 was cotransfected with HA-tagged ubiquitin and either
active HER2 or kinase-dead HER2 into HEK293 cells; CXCR4tion of cancer cells and their adhesion to endothelial cells in
responding to SDF-1 stimulation. Since SDF-1 is highly ex- was then immunoprecipitated, and the precipitate was immu-
noblotted with anti-HA antibody to detect HA-ubiquitin. Thepressed in metastatic organs such as lung, liver, and bone, this
finding provides in vitro support for a plausible mechanism for level of the ubiquitinated receptor was significantly lower in the
lysate from active HER2 transfection than that from kinase-deadHER2-enhanced metastasis and homing to metastatic organs
(please see the in vivo study later). form transfection (Figure 3D). This result further supported the
idea that HER2 inhibits CXCR4 ubiquitination and that HER2It should be mentioned that other mechanisms, in addition
to increased CXCR4 expression, might contribute to SDF- kinase activity is required for this action. Recently, it has been
shown that the Nedd4-like E3 ubiquitin ligase AIP4 mediates1-enhanced adhesion activity. We have previously shown that
the basal level of adhesion activity in MDA-MB-435 is not in- agonist-promoted ubiquitination of CXCR4 (Marchese et al.,
2003). To further investigate whether AIP4 might be involved increased by enforcing HER2 expression in the 435/HER2 cells
(Tan et al., 1997). Consistent with this notion, we noticed that HER2-mediated CXCR4 upregulation, we cotransfected HA-
tagged CXCR4, HER2, and either AIP4 or its catalytically inactiveSDF-1 did not stimulate adhesion activity in both 435 and 435/
HER2 cells; accordingly, the CXCR4-blocking antibody did not mutant C830A at the ratio of 1:2:4, then measured CXCR4 ex-
pression using an anti-HA antibody (Figure 3E). As expected,affect the adhesion activity of 435/neo and 435/HER2 cells (data
not shown). Thus, other mechanisms must be involved in en- HER2 enhanced CXCR4 expression (lanes 1 and 2), which was
completely suppressed in the presence of AIP4 E3 ligase (laneshancing the basal level of adhesion activity in MDA-MB-435
cells. Further investigation is required to determine whether 3 and 4). However, C830A did not suppress HER2-induced
CXCR4 expression (lanes 5 and 6). These results indicated thatthis mechanism is through a CXCR4-independent pathway or
downstream signaling of CXCR4. AIP4 inhibits HER2-induced CXCR4 expression. Taken to-
gether, HER2 inhibits ligand-induced CXCR4 ubiquitination and
then prevents CXCR4 from ligand-induced degradation.HER2 protects CXCR4 from ligand-induced
protein degradation
Although CXCR4 guides malignant cancer cells to metastatic CXCR4 is required for HER2-induced
lung metastasis in vivoorgans in which SDF-1 is enriched (Muller et al., 2001), stimula-
tion of SDF-1 can degrade CXCR4 (Marchese and Benovic, To gather further support for the idea that CXCR4 is required
for HER2-induced in vitro invasion and to determine whether2001). Therefore, we would expect that once the malignant
cancer cells reached the SDF-1-enriched organs, partial CXCR4 CXCR4 is also required for HER2-induced metastasis in vivo,
we designed a retroviral RNAi vector (pSR) to inhibit CXCR4would be degraded, which would reduce the ability to contribute
to other steps in metastasis, such as adhering to the endothe- expression (Brummelkamp et al., 2002) (Figure 4). The retrovirus
expressing small interfering RNA (siRNA) against CXCR4 waslium and invading the basement membrane. However, the above
results (Figures 2A–2H) suggest that CXCR4 may have a role used to infect 435/HER2 transfectants, and the puromycine-
resistant stable colonies were pooled together and namedin invasion, migration, and adhesion activity in the SDF-1-
enriched organs. Thus, we investigated whether HER2 overex- 435HER2/SR-iCXCR4. A similar control pool infected with the
retrovirus containing an empty vector was selected and namedpression might prevent CXCR4 from SDF-1-induced degrada-
tion. We examined the CXCR4 downregulation rate following 435HER2/SR-Ctrl. As expected, CXCR4 expression was re-
duced in the 435HER2/SR-iCXCR4 cells (Figure 4A), and theirSDF-1 stimulation by FACS and found that the CXCR4 level
quickly decreases; after about 1 hr of SDF-1 stimulation, the invasive activity was significantly decreased to a level compara-
ble to that of the negative control 435/neo cells (Figure 4B). TheCXCR4 level in MDA-MB-435 cells was 60% of that in untreated
cells, consistent with a previous report (Marchese and Benovic, positive control 435HER2/SR-Ctrl cells maintained a high level
of invasive activity (Figure 4B). Hence, the siRNA approach2001). However, the CXCR4 level remained almost the same in
the 435/HER2 cells after ligand stimulation for 1 hr (Figure 3A). further supports our findings that CXCR4 is required for HER2-
induced invasive activity in responding to SDF-1 stimulation.We further used the pulse-chase assay to detect the degrada-
tion rate of CXCR4 following SDF-1 stimulation and found that We next determined the in vivo metastatic potential of
CXCR4 siRNA stable and control transfectants in 435/HER2HER2 significantly lowers the ligand-induced protein degrada-
tion rate of CXCR4 (Figure 3B). The data indicated that HER2 and 435/neo cell lines by using the experimental metastasis
assay. The mice were euthanized 120 days after injection withprotects CXCR4 from ligand-induced downregulation. Thus, in
HER2-overexpressing cancer cells, CXCR4 may not only play one of the above cell lines, and pulmonary and extrapulmonary
metastases were examined. While the HER2 significantly in-a role in homing to the metastatic organs, but also contribute
to the invasive processes including enhanced migration and creased lung metastasis, as reported previously (Tan et al.,
1997), the number of metastatic lung nodules in the mice in-adhesion activity in the SDF-1-enriched organs.
CXCR4 degradation correlates with its ubiquitination status jected with 435HER2/SR-iCXCR4 was significantly lower than
that in the control mice (p  0.01) (Figures 4C and 4D). In(Marchese and Benovic, 2001), and ubiquitination of CXCR4
serves as a targeting signal for lysosomal degradation. To further addition, only two of the ten mice in the 435HER2/SR-iCXCR4
groups developed lung metastases, compared with eight of tenaddress the molecular mechanism of HER2 protection of CXCR4
from ligand-induced degradation, we next investigated the role mice in the control 435HER2/SR-Ctrl group (Table 1). Both the
size of the lung metastases and the total lung weight wereof HER2 on ubiquitination of CXCR4. In the presence of SDF-
1, HER2-expressing cells exhibit a reduced level of ubiquinated significantly lower in the 435HER2/SR-iCXCR4 group (Table 1
and Figure 4D). All the metastatic tumors were confirmed byCXCR4 (Figure 3C), suggesting that HER2 inhibits CXCR4 mo-
noubiquitination. To further support this notion, myc-tagged pathological examination (data not shown). Taken together,
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Figure 3. HER2 protects SDF-1-induced downregulation of CXCR4
A: HER2 prevents SDF-1-induced downregulation of CXCR4. After cycloheximide treatment (30 min), SDF-1 was added, the endogenous expression of
cell surface CXCR4 was analyzed by FACS at different time points, and the mean percentages of CXCR4 fluorescence were plotted. Representative FACS
assay results are shown to compare CXCR4 expression before SDF-1 stimulation (green) and 1 hr poststimulation (red).
B: Pulse-chase assay to measure the protein degradation rate under the SDF-1 stimulation: the means of the relative density were plotted in the bottom
panel. All the experiments were repeated three times.
C and D: HER2 inhibits SDF-1-induced ubiquitination of CXCR4. C: Serum-starved 435/neo and 435/HER2 cells were pretreated with the cycloheximide
treatment for 30 min and then treated with SDF-1 for 1 hr, and the endogenous expression of cell surface CXCR4 was immunoprecipitated and blotted
with monoclonal anti-ubiquitin antibody. D: HEK293 cells were transfected with Myc-tagged CXCR4 and HA-tagged ubiquitin plus either HER2 or kinase-
dead form K753M. Cells were incubated in the absence or presence of 100 nM SDF-1 for 1 hr at 37C. Proteosome inhibitor MG 132 was added with SDF-
1 serving as positive control. Receptors were immunoprecipitated, and membranes were blotted with an anti-HA antibody to detect the incorporation
of epitope-tagged ubiquitin. Under these conditions, ubiquitinated receptor was slightly detectable in cells expressing HER2 but was increased and easily
detected in cells expressing kinase-dead form K753M. Total cell lysates were also subjected to immunoblotting to detect the expression of CXCR4 and
HER2.
E: Effect of AIP4 and its catalytically inactive mutant C830A on HER2 mediated the upregulation of CXCR4. We cotransfected HA-tagged CXCR4, HER2,
and either AIP4 or its catalytically inactive mutant C830A at the ratio of 1:2:4, then measured CXCR4 expression using an anti-HA antibody.
these results clearly show that the inhibition of CXCR4 by stable as CXCR4 high. We found a significantly positive correlation
between HER2 and CXCR4 expression (Figure 5A and TablesiRNA reduces HER2-induced lung metastasis and that CXCR4
is required for HER2-mediated lung metastasis in vivo. 2). In human breast tumor tissues in which HER2 expression
was positive, CXCR4 expression was also positive (case 1 in
Figure 5A), whereas in HER2-negative tumor tissues, CXCR4CXCR4 is upregulated in HER2-overexpressed primary
breast tumor tissues and is correlated expression was also undetectable (case 2 in Figure 5A). It should
be mentioned that the two images (top left and right, or bottomwith poor patient survival
To determine whether HER2-enhanced CXCR4 expression is left and right) were derived from nearby sections of the same
tumor tissue. Among the 219 breast cancer tumor tissue sam-also observed in primary tumor tissues, we performed immuno-
histochemical staining and scoring analysis (Camp et al., 1999; ples that we examined, the correlation between HER2 and
CXCR4 was statistically significant (p0.001; Table 2), support-Zhou et al., 2001). Immunohistochemical scoring (H score) was
determined by multiplying the staining intensity by the percent- ing the conclusion that overexpression of HER2 upregulates
CXCR4 expression in vivo. Importantly, CXCR4 expression wasage of positive tumor cells (Camp et al., 1999). According to
bimodal H score distribution, tissues with scores 130 were also found to be correlated with poor patient overall survival
(p  0.05) (Figure 5B). These results further support the ideadesignated as CXCR4 low, and scores 130 were designated
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Figure 4. CXCR4 is required for HER2-mediated
lung metastasis in vivo
A: FACS analysis of retroviral CXCR4 siRNA stably
transfected HER2/435 cells, 435HER2/SR-iCXCR4
(red), and its vector control cells (435HER2/SR-
Ctrl) (blue) after puromycine selection.
B: Invasion analysis of the retroviral CXCR4 siRNA
transfected HER2/435 (435HER2/SR-iCXCR4) cells
and the control cells (435HER2/SR-Ctrl).
C: In vivo lung metastasis driven by HER2 is re-
duced by CXCR4 inhibition. The mice were eu-
thanized 120 days after injection, and the num-
ber of lung metastasis nodules larger than 0.5
mm in diameter in each group was examined.
*p  0.05; **p  0.01.
D: A representative set of gross lungs with meta-
static nodules.
that HER2 overexpression enhances CXCR4 expression and pression is a known marker of poor prognosis in breast cancer,
our observations add strong clinical support for the identifiedindicate that CXCR4, like HER2 (Slamon et al., 1989), also serves
as a predictor for poor overall patient survival. mechanism, namely HER2 enhancement of CXCR4 expression.
Cancer metastasis results from several highly organized se-
quential steps involving numerous interactions between the can-Discussion
cer cells and host, but the detailed molecular mechanism is still
not completely understood (Steeg, 2003; Yeatman and Nicol-The RTK HER2 and the GPCR CXCR4 are two structurally unre-
lated receptors, but the current study demonstrates that HER2 son, 1993). CXCR4 is involved in breast cancer metastasis to
specific organs (Liotta, 2001; Muller et al., 2001); however, theenhances CXCR4 expression and that CXCR4 is required for
HER2-induced lung metastasis, therefore resolving a longstand- detailed mechanism of CXCR4 upregulation in malignant cancer
remains poorly understood. Recently, CXCR4 was found to being puzzle of how HER2 overexpression guides cancer cells to
home to their metastatic organs. CXCR4 expression was recently transactivated by hypoxia-induced factor-1 (HIF-1) at the
transcriptional level in von Hippel-Lindau mutated renal cell car-found to be correlated with lymph node metastasis in a 79-case
cohort of patients with invasive ductal carcinoma (Kato et al., cinoma (Bernards, 2003; Staller et al., 2003), which serves as
one plausible mechanism for CXCR4 upregulation. In the current2003). In our 219-case breast cancer study, CXCR4 was further
found to be associated with poorer patient survival, and a sig- study, we identified two distinct mechanisms for CXCR4 up-
regulation by HER2 overexpression, enhancement of CXCR4nificant correlation between HER2 and CXCR4 expression was
also observed (p 0.001). In view of the fact that HER2 overex- protein synthesis and inhibition of ligand-induced degradation.
Table 1. Inhibition of in vivo metastatic potential by CXCR4 siRNA
Frequency No. of nodules Size of nodules
(metastasis/total) (mean [range]) (range in mm) Lung weight (g)
435HER2/SR-Ctrl 8/10 26 (0–50) 0.5–8.9 7.8  3.4
435HER2/SR-iCXCR4 2/10** 2.5 (0–3)** 0.8–1.0 3.0  0.7**
435neo/SR-Ctrl 3/7* 6.3 (0–8)* 0.5–4.0 3.1  0.6*
435neo/SR-iCXCR4 1/7 2 (0–2) 0.5–1.0 2.8  0.6
An experimental metastasis assay was used to determinate in vivo lung metastatic potential among MDA-MB-435cells, HER2 stable transfectants, and
CXCR4 siRNA stable transfectants. The mice were euthanized 120 days after tail vein injection, and the frequency, number, and size of lung metastases
and the whole lung weight were measured. Lung nodules 0.5 mm in diameter were counted. Student’s t test was used to compare differences between
each group. *Compared with the 435HER2/SR-Ctrl, p  0.05. **Compared with the 435HER2/SR-Ctrl, p  0.01.
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Table 2. Summary of HER2 and CXCR4 immunohistochemical staining
in tumor tissue sample from 219 cases primary breast cancer
CXCR4 Total
 
HER2/neu  116 (81.7%) 26 (18.3%) 142
 29 (37.7%) 48 (62.3%) 77
Total 145 74 219
The 219 surgical specimens of breast tumor were stained with anti-HER2
and anti-CXCR4 antibody as shown in Figure 5. Expression patterns in all
samples are summarized here. The Pearson chi-square was used to analyze
for significance of the relationship between CXCR4 expression and HER2
expression (p  0.001).
kine and is expressed constitutively in some tissues, including
bone marrow and lung, which are major homing organs for
metastatic breast cancer (Muller et al., 2001; Nagasawa et al.,
1996). SDF-1 is present in serum at low concentrations, but
in an inactive form (Villalba et al., 2003). Thus, serum SDF-1
may not affect homing of CXCR4-expressing cancer cells. In
addition to attracting CXCR4-expressing malignant cancer cells
to certain organs (Muller et al., 2001), SDF-1 can also induce
CXCR4 degradation (Marchese and Benovic, 2001). This raises
the interesting question of whether CXCR4 could be involved
in multiple-step metastatic processes, such as invasion through
the basement membrane and adherence to endothelial cells,
which are critical in the extravasation process for cancer cells
to leave the circulation and migrate into normal organs. Our results
(Figure 2) clearly indicate that CXCR4 is required for invasion,
migration, and adhesion activities under SDF-1-stimulated condi-Figure 5. Correlation between CXCR4 and HER2 expression in human breast
tumor tissues tions, suggesting that CXCR4 may play a role in these steps
A: Representative human primary breast tumor tissue samples with immuno- toward malignant metastases. Blockage of SDF-1-induced
histochemical staining. Case 1: HER2-positive staining (top left) and CXCR4 CXCR4 downregulation by HER2 (Figure 3) provides a plausible
expression-positive staining (top right). Case 2: HER2-negative staining (bot-
mechanism to allow continuing CXCR4 expression, which sug-tom left) and CXCR4-negative staining (bottom right). The two samples
came from nearby tumor sections. Original magnification, 400	. gests that CXCR4 not only plays a role in homing to the meta-
B: Kaplan-Meier analysis of overall survival in patients with breast cancer static organs, but also contributes to invasive processes, such
carcinoma according to their CXCR4 expression levels (p  0.05).
as enhanced migration and adhesion activity, in SDF-1-enriched
organs for HER2-overexpressing cancer cells. It is not yet clear
whether malignant cancer cells in which HER2 is not overex-
pressed acquire a similar mechanism to prevent CXCR4 degra-Presently, the detailed molecular mechanisms for receptor en-
dation by SDF-1 or if they activate other mechanisms to con-docytosis, endosome sorting, and degradation of GPCRs, in-
tribute to invasion and adhesion activities in the extravasationcluding CXCR4, are not completely understood (Shenoy et al.,
process. The MDA-MB-435 metastatic breast cancer cell line,2001). Recently, it has been suggested that the mechanisms
which does not overexpress HER2, has acquired a strong adhe-involved in CXCR4 ubiquitination and sorting may share some
sion activity through other mechanisms, as HER2 does not en-common features with EGFR endocytosis and degradation pro-
hance its ability to adhere to endothelial cells (Tan et al., 1997)cesses, although they are structurally unrelated membrane re-
and a CXCR4-blocking antibody does not affect its adhesionceptors (Hendriks et al., 2003; Lloyd et al., 2002; Marchese
activity (data not shown).et al., 2003; Polo et al., 2002; Worthylake et al., 1999). One
In summary, HER2 upregulates the expression of CXCR4,mechanism to degrade CXCR4 is internalization of CXCR4
which is required for HER2-enhanced invasion, migration, adhe-through early endosomes, and then sorting into late endosomes
sion, and metastasis to the lung. CXCR4 expression is corre-and lysosomes. HER2 may inhibit CXCR4 ubiquitination and
lated with overall patient survival in breast cancer. Similar toabrogate subsequent sorting steps and therefore prevent its
HER2, this observation will have important clinical implications.degradation. Taken together, CXCR4 expression can be regu-
The study of linkage between these two structurally unrelatedlated through different mechanisms. It would be interesting to
membrane receptors, HER2 and CXCR4, both of which playexplore when and where each mechanism is used to regulate
critical roles in cancer metastasis, has advanced our knowledgeCXCR4 expression.
The CXCR4 ligand SDF-1 is a locally secreted small cyto- of how HER2-overexpressing cancer cells home to their meta-
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incubating the cells with 100 ng/ml SDF-1 for 1 hr at 37C. Cell-to-cellstatic organs. It may also help us to better understand molecular
adhesion then proceeded for 30 min at 37C. OD was measured at 490 nm.mechanisms of cancer metastasis.
Retroviral siRNA stable cell linesExperimental procedures
Retroviral siRNA vector (pSUPER.RETRO) was purchased from OligoEngine
(Seattle, WA) (Brummelkamp et al., 2002). The CXCR4 RNAi primers wereCell lines, DNA constructs, and antibodies
5
-GATCCCCTGGATTGGTCATCCTGGTCTTCAAGAGAGACCAGGATGACAll cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM)/
CAATCCATTTTTGGAAA-3
 and 5
-AGCTTTTCCAAAAATGGATTGGTCATCF12 supplemented with 10% fetal bovine serum. Cell line NIH3T3 subtype
CTGGTCTCTCTTGAAGACCAGGATGACCAATCCAGGG. Control primersand its HER2 stable transfectant and human breast cancer cell line MDA-
were 5
-GATCCCCTTTTTGGAAA-3
 and 5
-AGCTTTTCCAAAAAGGG-3
.MB-435 and its two HER2 stable transfectants have been described pre-
The retrovirus was produced using the Phoenix Retroviral System (Orbigen,viously (Tan et al., 1997, 2002; Yu and Hung, 2000; Zhou et al., 2001).
San Diego, CA). Cells were infected with retroviral supernatant and selectedHA-CXCR4 and FLAG-ubiquitin constructs were kindly provided by Dr. Be-
in puromycine medium. CXCR4 expression was confirmed by FACS.novic (Marchese et al., 2003); wild-type and catalytically inactive AIP4 plas-
mids were kindly provided by Dr. Tony Pawson. The anti-myc and anti-HA
Experimental metastasis assaypolyclonal antibodies were purchased from Sigma-Aldrich. siRNA directed
Eight-week-old female nude mice (Charles River, Wilmington, MA) were usedagainst human HER2 was from Dharmacon Research. SDF-1 and CXCR4
in the experimental metastasis assay described previously (Tan et al., 1997).antibodies (MAB170, MAB172) were from R&D systems. Other CXCR4 anti-
The mice were euthanized 120 days after the injection of cancer cells. Thebodies were from Abcam and Lab Vision/Neomarkers. The monoclonal anti-
animal experiments were approved and in compliance with the institution’subiquitin antibody (6C1) was from Sigma.
guidelines.
Immunoprecipitation and Western blotting
Immunoprecipitation and Western blotting were performed as described Immunohistochemical staining and analysis
previously (Li et al., 2003), with 1 g of antibody against CXCR4 or normal Human breast cancer tissue samples were collected and stained, as de-
control IgG in 1.0 mg whole lysate protein. scribed before (Deng et al., 2002; Zhou et al., 2001) with anti-human CXCR4
monoclonal Ab (MAB170; 1:400 dilution) and anti-human HER2 Ab (DAKO;
FACS and immunofluorescent staining 1:100). CXCR4 positivity was assessed semiquantitatively using staining
For FACS analysis, cells were treated with mouse anti-CXCR4 antibody intensity and percentage by two independent pathological investigators. H
(MAB172; R&D systems, Minneapolis, MN) or normal IgG overnight at 4C score was determined by multiplying the staining intensity by the percentage
and then stained with FITC-conjugated IgG at room temperature for 30 min of positive tumor cells (Camp et al., 1999). Chi-square analysis was used to
and analyzed with a Becton Dickinson flow cytometer (Franklin Lakes, NJ). analyze the relationship between CXCR4 and HER2 expression. The Kaplan-
For the ligand-induced receptor degradation, serum-starved cells were pre- Meier method was used to analyze breast cancer patient overall survival.
treated with 20 g/ml cycloheximide for 30 min, and then SDF-1 (R&D Statistical significance was defined as p  0.05.
Systems) was added to the final concentration of 100 ng/ml for 1 to 4 hr.
Immunofluorescent staining was performed as described previously (Zhou Acknowledgments
et al., 2001).
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